169 The use of Airvo™ high flow humidification with cystic fibrosis patients – development of the service

Objectives Delivery of adequate humidification for patients with or without an oxygen (O 2 ) requirement is challenging for patients with Cystic Fibrosis. In 2013 we did a pilot study using Airvo™, results showed it to be a useful and popular additional treatment. Subsequent to this we purchased more units, using them with a wider spectrum of patients. Methods We have four units in total. The units can provide heated humidification with/without an O 2 requirement, range of temperature (31–37°C), with facemask or nasal interface option. We analysed the data over a 12 month period reviewing patient notes/identifying common themes. Results 30 patients over 43 episodes of care were treated using the Airvo™, for a total of 607 days. The number of days required ranged from 1 to 79 (mean 14): O 2 requirements ranged from 0 to FiO 2 90. Twenty-two of the episodes of Airvo™ use were for humidification only, 220 days (mean 10): 21 episodes were for O 2 and humidification, total 387 days (mean 18.4). Patients needing O 2 and humidification on average required Airvo™ for an additional 8 days. In 38/43 of the episodes of care using Airvo™, patients were using mucolytics regularly prior to admission. Of the interfaces, 23 patients elected to use the facemask, with 20 using the nasal interface. Conclusion We are now using Airvo™ more as standard practice, for both the patients with an O 2 requirement and those just requiring humidification. The facemask and nasal interface options are both used, increasing the application tolerance significantly. Frequently there are more patients suitable for treatment with the units, than units themselves. Our vision is to have one available for every in-patient.